Taormina D, Abdallah H Y, Venkataramanan R, Logue L, Burckart G J, Ptachcinski R J, Todo S, Fung J J, Starzl T E
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, PA 15261.
Am J Hosp Pharm. 1992 Jan;49(1):119-22.
The effects of the diluent, the storage container, light, and infusion through various types of tubing on the stability and sorption of FK 506 were studied. Solutions of FK 506 in 0.9% sodium chloride injection or 5% dextrose injection were stored at room temperature (24 +/- 2 degrees C) in glass i.v. bottles, polyvinyl chloride (PVC) minibags, and polyolefin containers. FK 506 solution in 0.9% sodium chloride injection was stored in plastic syringes at room temperature and either exposed to normal room light or stored in the dark. FK 506 solution in 5% dextrose injection was placed in plastic syringes and infused through PVC anesthesia extension tubing, PVC i.v. administration set tubing, and fat emulsion tubing over a two-hour period. The infused samples and samples collected from the containers and syringes at intervals up to 48 hours were analyzed for FK 506 concentration by high-performance liquid chromatography. FK 506 concentrations remained greater than 90% of initial concentration for admixtures in 5% dextrose injection stored in glass bottles for 48 hours and for admixtures in 5% dextrose injection or 0.9% sodium chloride injection stored in polyolefin containers for 48 hours. No change in concentration was measured for admixtures in 0.9% sodium chloride injection stored in plastic syringes, and exposure to light did not affect the stability of FK 506 solution. No substantial change in concentration occurred in FK 506 solution in 5% dextrose injection infused through PVC anesthesia extension tubing, PVC i.v. administration set tubing, or fat emulsion tubing. FK 506 admixtures prepared with 5% dextrose injection or 0.9% sodium chloride injection should be stored in polyolefin containers. If polyolefin containers are not available, solutions should be prepared with 5% dextrose injection and stored in glass bottles.
研究了稀释剂、储存容器、光照以及通过各种类型输液管输注对FK 506稳定性和吸附性的影响。FK 506在0.9%氯化钠注射液或5%葡萄糖注射液中的溶液于室温(24±2℃)下分别储存在玻璃静脉输液瓶、聚氯乙烯(PVC)迷你袋和聚烯烃容器中。0.9%氯化钠注射液中的FK 506溶液于室温下储存在塑料注射器中,要么暴露于正常室内光照下,要么避光储存。5%葡萄糖注射液中的FK 506溶液置于塑料注射器中,并通过PVC麻醉延长管、PVC静脉输液管和脂肪乳剂管在两小时内输注。通过高效液相色谱法分析在长达48小时的间隔时间从容器和注射器中收集的输注样品以及样品中的FK 506浓度。对于储存在玻璃瓶中48小时的5%葡萄糖注射液中的混合物以及储存在聚烯烃容器中48小时的5%葡萄糖注射液或0.9%氯化钠注射液中的混合物,FK 506浓度保持在初始浓度的90%以上。储存在塑料注射器中的0.9%氯化钠注射液中的混合物未检测到浓度变化,且光照不影响FK 506溶液的稳定性。通过PVC麻醉延长管、PVC静脉输液管或脂肪乳剂管输注的5%葡萄糖注射液中的FK 506溶液浓度未发生实质性变化。用5%葡萄糖注射液或0.9%氯化钠注射液配制的FK 506混合物应储存在聚烯烃容器中。如果没有聚烯烃容器,溶液应用5%葡萄糖注射液配制并储存在玻璃瓶中。